ABSTRACT: Introduction: Osteogenesis imperfecta (OI) is characterized by skeletal fragility and muscle weakness. In this study we investigated the effects of soluble activin type IIB receptor (sActRIIB-mFc) on muscle mass and function in 2 distinct mouse models of OI: osteogenesis imperfecta murine (oim) and 1/ G610C. Methods: Wild-type (WT), 1/G610C, and oim/oim mice were treated from 2 to 4 months of age with Tris-buffered saline (vehicle) or sActRIIB-mFc and their hindlimb muscles evaluated for mass, morphology, and contractile function. Results: sActRIIB-mFc-treated WT, 1/G610C, and oim/oim mice had increased hindlimb muscle weights and myofiber cross-sectional area compared with vehicle-treated counterparts. sActRIIB-mFctreated oim/oim mice also exhibited increased contractile function relative to vehicle-treated counterparts. Discussion: Blocking endogenous ActRIIB was effective at increasing muscle size in mouse models of OI, and increasing contractile function in oim/ oim mice. ActRIIB inhibitors may provide a potential mutationspecific therapeutic option for compromised muscle function in OI.
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Muscle Nerve 57: 294-304, 2018 Sarcopenia is one of the most common pathophysiological outcomes associated with aging, resulting in reduced muscle mass with substantial changes in muscle fiber type from oxidative to glycolytic. 1 Consequences of reduced muscle mass and strength often lead to increased fall risk and fractures, which are in part strongly influenced by cross-talk of the muscle-bone units. Frost's mechanostat theory suggests that bone is mechanosensitive and that muscle mass and contractile force elicit peak voluntary mechanical load on bone. 2 Indeed, many patients with sarcopenia are likely to develop osteoporosis and osteopenia as well. [3] [4] [5] [6] [7] [8] [9] Sarcopenia and osteoporosis are not only associated with aging, but are also present in many disease states, including cancer cachexia, muscular dystrophies, and osteogenesis imperfecta (OI). [10] [11] [12] Osteogenesis imperfecta, also known as brittle bone disease, is a heritable connective tissue disorder characterized by compromised biomechanical integrity in type I collagen-containing tissues, including bone, vasculature, skin, and tendon. 13 More than 85% of individuals with OI have mutations in their type I collagen genes, COL1A1 or COL1A2, whereas the remaining 15% have mutations in the genes of proteins associated with type I collagen assembly, mineralization, or osteoblast function. 13 The majority of the clinical and basic research in OI has been targeted toward improving bone directly. Although the correlation between muscle and bone strength is well established, muscle function and pathology in OI has only just begun to be investigated. The limited number of studies evaluating muscle function in type I and type III OI patients reported reduced muscle strength. [14] [15] [16] [17] Muscle function has also been evaluated in 2 different mouse models of OI. The moderately severe recessive osteogenesis imperfecta murine (oim) mouse model showed an inherent muscle pathology with reduced skeletal muscle mass and contractile function, 12 whereas the milder dominant negative OI mouse model, 1/G610C, did not. 18 Due to the importance of muscle-bone crosstalk in bone strength and quality, it is critical to understand muscle properties in OI, as improved muscle function is known to decrease fracture risk and may lead to improved bone strength and quality.
Myostatin, a well-known negative regulator of muscle growth, is a member of the transforming growth factor-b superfamily and binds to activin receptor type IIB to activate multiple intracellular signaling pathways to regulate gene expression.
Myostatin knockout mice exhibit muscle hypertrophy and hyperplasia. 20 Due to myostatin's impact on muscle, various therapeutic molecules have been developed to inhibit myostatin and have been evaluated in a diverse group of muscle-related disorders. [21] [22] [23] [24] [25] [26] Among these molecules, the soluble activin receptor type IIB-mFc has shown promising results in age-related sarcopenia, cancer cachexia, muscle dystrophy induced by hypoxic conditions, and muscular dystrophic disease. [22] [23] [24] [25] 27, 28 The presence of muscle weakness in OI not only negatively impacts activities of daily living, but it may also contribute to skeletal fragility and increased fracture risk. In this study we sought to determine whether treatment with the soluble activin receptor type IIB decoy molecule (sActRIIB-mFc) would increase muscle mass and enhance contractile function in 2 molecularly distinct mouse models of OI, osteogenesis imperfecta murine (oim) and 1/G610C. Homozygous oim (oim/oim) mice have a functional null mutation in their Col1a2 genes, and thus compensate by making homotrimeric type I collagen, a1(I) 3 , instead of normal heterotrimeric type I collagen, a1(I) 2 a2(I), whereas the 1/G610C mice are heterozygous for a glycine-to-cysteine substitution at position 610 of the a2 chain of type I collagen. 29, 30 Genetically and phenotypically, the 1/G610C mouse models OI in affected family members of a large Amish kindred. 31 The oim/oim and the1/G610C mice model moderately severe human OI type III and milder to moderate OI type IV individuals, respectively. As previously reported, oim/oim mice exhibit a muscle pathology, with reduced muscle mass and absolute and specific peak tetanic forces, 12 whereas the 1/G610C mice do not. 18 In this study we investigated the impact of sActRIIB-mFc on muscle properties of 1/G610C and oim/oim mice to test the hypothesis that blocking the ligands that bind the endogenous activin receptor IIB by the sActRIIB-mFc decoy will increase hindlimb skeletal muscle weights and absolute muscle contractile strength regardless of the presence of muscle pathologies associated with mutations in type I collagen (glycine substitution vs. functional null Col1a2).
METHODS
Animals. Both OI mouse models, G610C (Col1a2 tm1.1Mcbr ) and oim (Col1a2 oim ), were bred and maintained on the C57BL/6J congenic background by repeatedly backcrossing into wild-type (WT) C57BL/6J mice (Stock No. 000664; Jackson Laboratory, Bar Harbor, Maine) to minimize potential modifier gene effects. The mice were genotyped as previously described 30, 32 and had ad libitum access to water and food (Purina 5008 Formulab Diet; Purina Mills, Inc., St. Louis, Missouri). The animals were housed in an AAALACaccredited facility at the University of Missouri and the study was performed in accordance with an animal care and use protocol approved by the University of Missouri.
Drug Administration. Male and female WT, 1/G610C, and oim/oim mice were each randomly distributed into 2 groups and treated biweekly with either vehicle [Tris-buffered saline (TBS)] as control or 10 mg/kg sActRIIB-mFc in TBS (RAP-031; Acceleron Pharma, Inc., Cambridge, Massachusetts) by intraperitoneal injection beginning at 2 months of age and continuing to 4 months of age. The 8-16-week treatment interval encompasses pubertal growth through skeletal maturity and was chosen to potentially maximize the impact of sActRIIB-mFc treatment on musculoskeletal development. 33 The 10-mg/kg dose of sActRIIB-mFc was previously found to significantly increase muscle mass, which was not further increased by a 30-mg/kg dose. 28 Animals were not randomized into treatment groups and the investigators were not blinded as to the identity of the animals. At 4 months of age, mice were anesthetized to evaluate hindlimb skeletal muscle contractility in situ, then euthanized, and the hindlimb skeletal muscles harvested for histologic evaluation, cross-sectional area measurement, and citrate synthase activity.
Contractile Properties. Contractile properties of the soleus (Sol), gastrocnemius (Gast), and tibialis anterior (TA) muscles in male and female WT, 1/G610C, and oim/oim mice treated with either vehicle or sActRIIB-mFc were determined, as previously described. 12 Briefly, mice were anesthetized and the left Sol, Gast, and TA muscles were surgically exposed at their distal insertions. The distal tendon of each muscle was attached to a Grass force transducer (ADInstruments, Colorado Springs, CO) and sequentially tested. The distal tendon was adjusted in length so that passive tension was 0 g. The sciatic nerve was isolated and placed on a stimulating electrode and a twitch was obtained, as described elsewhere. 12 At optimal length, a peak tetanic contraction (P o ) was elicited by pulses delivered at 150 HZ for a 300-ms duration and an intensity of 6 V for each type muscle. 34 All data were collected using PowerLab (ADInstruments, Colorado Springs, CO), and analyzed blind to genotype, sex, and treatment.
Tissue Harvest. After the contractile function testing, the left (stimulated) and right Sol, plantaris (Plant), Gast, TA, and quadriceps (Quad) muscles were removed, cleaned of extraneous tissue, blotted, and weighed. Left Sol, Gast, and TA muscles were then placed in 4% paraformaldehyde for 24 hours and then transferred to 70% ethanol for future staining with hematoxylin and eosin for morphologic evaluation. The right-side Gast was snap frozen in liquid nitrogen and stored at 280 8C for future quantitation of citrate synthase activity.
Histologic Evaluation and Cross-Sectional Myofiber
Measurements. Left-sided paraformaldehyde-and ethanolprepared muscles were transversely sectioned at the middle of the muscle belly, embedded in paraffin, and then sectioned at 5 mm and stained with hematoxylin and eosin (H&E). 12 An average of 300 myofibers were evaluated for morphology and evidence of damage or inflammation, and their myofiber cross-sectional areas were determined using ImageJ software (National Institutes of Health, Bethesda, Maryland). 12 Analyses were performed blind to genotype, sex, and treatment.
Citrate Synthase Activity. Citrate synthase was determined in mixed gastrocnemius muscle as a measure of mitochondrial content/function using the methods of Srere et al., as previously described. 35, 36 Locomotor Activity. Locomotor activity of WT and oim/ oim mice was monitored using open field test environment monitors (Med Associates, Georgia, Vermont) at 1, 2, 3, and 4 months of age, as described elsewhere. 18 Open Field Activity (Med Associates) software was used to evaluate the number of recorded sensor breaks and for converting the data into distance traveled (cm). Mice were placed individually into the chamber for 60 min/day for 5 consecutive days. The animals were acclimated on the first 2 days and the data from days 3-5 were summated and used in the statistical analyses.
Statistical Analyses. Statistical analyses were performed using SAS software (SAS Institute, Inc., Cary, North Carolina). Data were analyzed as a 3 3 2 3 2 factorial [3 genotypes, 2 sexes and 2 treatments (vehicle and sActRIIB-mFc)] using the Fisher protected least significant difference test. 37, 38 Locomotor activity data were analyzed as a 2 3 2 3 4 factorial (2 genotypes, 2 sexes, and 4 time-points). Genotype and sex interactions and the genotype and sex main effects were evaluated. Body, muscle, and relative muscle weights (Gast, TA, and Sol), muscle contractile function (Gast and Sol), muscle myofiber cross-sectional area (Gast and Sol), and activity levels exhibited a main genotype effect, allowing pooling of genotype-matched male and female values in the absence of genotype and sex interactions. The main genotype effect values for these parameters are presented as the least-squares mean (LSmean) 6 standard error (SE). Genotype and sex interactions were present only for the TA myofiber crosssectional area and contractile generating force. Tables S1-4 (refer to Supplementary Material, available online) list the body, muscle, and relative muscle weights, muscle contractile function, and muscle myofiber cross-sectional area (mean 6 SE) separated by sex, treatment, and genotype. If heterogeneous variations were present, a log transformation was used to stabilize the variation. If the log transformation failed to stabilize the variation, a nonparametric ranked analysis was performed according to Conover and Iman 39 Differences were considered to be significant at P 0.05.
RESULTS
Body Weights. Vehicle-treated oim/oim mice had lower body weights compared with both WT and 1/ G610C counterparts, whereas sex-and treatmentmatched 1/G610C and WT mice were equivalent (Fig. 1 ). Mice treated with sActRIIB-mFc exhibited differences in body weights after 1 week of treatment (after the second injection) compared with vehicle-treated control mice, regardless of genotype and sex (Fig. 1) . At 4 months of age, sActRIIB-mFctreated male and female mice had 20% and 24% increases in body weight, respectively, compared with their vehicle-treated counterparts, regardless of genotype (Fig. 1) .
Muscle Weights. The hindlimb skeletal muscles (Sol, Plant, Gast, TA, and Quad) of the vehicletreated oim/oim mice exhibited reduced muscle wet weights compared with both WT and 1/G610C counterparts, whereas there were no differences in the hindlimb muscle weights of WT and 1/G610C mice ( Fig. 2 ; see also Tables S1 and S2 in the Supplementary Material online). Mice treated with sActRIIBmFc exhibited increases in muscle wet weights of all 5 hindlimb skeletal muscles compared with their vehicle-treated counterparts, regardless of genotype (Fig. 2) . The effects of genotype and sActRIIB-mFc treatment were still evident when muscle masses were normalized to their body weights [relative muscle weights (muscle wet weight/body weight)], except for sActRIIB-mFc-treated Sol muscles for the 3 genotypes and Gast muscle for WT and oim/oim mice (Fig. 3 , and Tables S1 and S2 online). When muscle masses were normalized to their femur length, the sActRIIB-mFc treatment effects were still evident in all genotypes regardless of muscle groups, suggesting the increased body weight was due to increases in muscle mass (data not shown).
Muscle Histology and Myofiber Cross-Sectional Area. Histological evaluation showed no evidence of necrosis, degeneration, or regeneration in vehicle or sActRIIB-mFc-treated WT, 1/G610C, and oim/oim mouse skeletal muscle morphology (Fig. 4A-F , and  Tables S3 and S4 online) . sActRIIB-mFc-treated WT and 1/G610C mice myofiber cross-sectional areas (CSAs) were increased in the Sol, Gast, and TA muscles compared with their vehicle-treated counterparts (Sol: WT 22%, 1/G610C 21%; Gast: WT 20%, 1/G610C 26%; TA: male WT 59%, male 1/G610C 59%, female WT 35%, female 1/G610C 12%; Fig.  4G-I ). For the oim/oim mice, only the female oim/oim TA muscle exhibited increased myofiber CSA in response to sActRIIB-mFc treatment (Fig. 4I) .
Muscle Contractile Generating Capacity. The Sol, Gast, and TA muscles of the 1/G610C mice exhibited equivalent levels of absolute whole muscle contractile generating capacity [peak tetanic force (P o ; g)], relative contractile generating capacity [relative P o ; peak tetanic force (P o ; g)/muscle weight (mg)], and specific contractile generating capacity [specific P o ; peak tetanic force (P o ; g)/muscle myofiber CSA (lm 2 ] compared with their WT counterparts, regardless of sActRIIB-mFc treatment, except for the male relative and specific P o of TA muscle and pooled specific P o of Gast muscle (Figs. 5 and 6, and Tables S3 and S4 online). Vehicle-treated oim/oim mice had reduced peak tetanic force in Sol, Gast, and TA muscles, and reduced relative P o and specific P o in Gast and TA muscles compared with their WT counterparts (Figs. 5 and 6 ). sActRIIB-mFctreated WT and 1/G610C mice had 22% and 24% increases in Sol P o and 11% and 5% increases in Gast P o , respectively, although they did not reach significance. sActRIIB-mFc-treated oim/oim mice exhibited 41% (Sol muscle), 35% (Gast muscle), 43% (male TA muscle), and 27% (female TA muscle) increases in peak tetanic force compared with vehicle-treated counterparts (Fig. 5) . When normalized to muscle size, the relative P o of the Sol muscle in the oim/oim mouse was still greater with sActRIIBmFc treatment (Fig. 5) . Interestingly, the relative P o values of the Gast and TA muscles were decreased in sActRIIB-mFc-treated WT and 1/G610C mice compared with their vehicle-treated counterparts (Fig.  5 ). The specific P o values of the TA muscles were decreased in male WT and 1/G610C mice, and the specific P o in Gast muscle was decreased in 1/ G610C mice with sActRIIB-mFc treatment compared with their vehicle-treated counterparts (Fig. 6) .
Citrate Synthase Activity. The oim/oim Gast muscle exhibited a 16% increase in citrate synthase activity compared with WT counterparts, where the levels of 1/G610C Gast citrate synthase activity were equivalent to their WT counterparts (Fig. 7) . There was no change in citrate synthase activity with sActRIIB-mFc treatment, regardless of genotype.
Locomotor Activity Levels. The oim/oim mice had reduced locomotor activity levels at 1, 2, and 4 months of age when compared with WT mice (Fig. 8 ).
DISCUSSION
Consistent with the previous studies, oim/oim mice exhibited reduced body weight, muscle mass, and contractile function compared with WT littermates, whereas the 1/G610C mice did not exhibit any muscle pathology (Figs. 1, 2 and 5) . 12, 18 Similar to our findings in OI mouse models, several clinical studies of muscle function found that individuals with type I, III, and IV OI exhibited decreased ambulation with reduced muscle strength, and exercise capacity.
14-17,40,41 Brizola et al. suggested that the level of ambulation and muscle function in OI were inversely correlated with the severity of bone deformity, regardless of OI type. 17 Palomo et al. reported reduced transverse forearm muscle CSA in OI type I and III patients, but not in type IV patients; however, there were no functional data. 41 Interestingly, 1/G610C, which models type IV human OI, did not exhibit a muscle pathology or differences in activity levels relative to WT mice. 18 This could reflect species differences and/or mutation-specific effects.
Our findings demonstrate an increase in body size and hindlimb skeletal muscle weights with systemic administration of sActRIIB-mFc in WT, 1/ G610C, and oim/oim mice, potentially due to increased myofiber CSA, suggesting that inhibition of myostatin via sActRIIB-mFc is effective at increasing muscle mass regardless of the presence or absence of OI muscle pathology. Increased muscle mass was associated with increased absolute muscle contractile function without altered relative and specific muscle contractile function in sActRIIB-mFc-treated oim/oim mice. Similarly, DiGirolamo and colleagues showed increased muscle mass with 4-week administration of soluble activin receptor IIB in oim/oim mice, although the increases in limb muscle weights did not always reach significance and were not as great as the impact on pectoralis muscle. 22 We demonstrated increases in all 5 hindlimb skeletal muscles weights with sActRIIB-mFc treatment. The difference in magnitude of the response likely reflects the The oim/oim mice exhibited reduced average muscle myofiber CSA compared with WT and 1/G610C counterparts. sActRIIB-mFctreated WT and 1/G610C mice exhibited increased muscle myofiber CSA compared with vehicle-treated counterparts. (G) Sol myofiber CSA, (H) Gast myofiber CSA, and (I) TA myofiber CSA (n 5 9-12 per group; TA muscle groups: n 5 4-7). The genotype main effect was evaluated. Gast and Sol values are presented as least-squares mean 6 standard error of the combined genotype values, regardless of sex, and the TA exhibited a genotype 3 sex interaction, with values (least-squares mean 6 standard error) separated by sex and genotype. *P < 0.05 and † P < 0.05 vs. WT 1 vehicle-treated mice. duration and frequency of treatment (once per week for 4 weeks vs. biweekly for 8 weeks) and the age of treatment initiation (12 weeks vs. 8 weeks of age). Twelve-week-old mice are adult mice near skeletal maturity, whereas 8-week-old mice are still within a more rapid growth period and may be more responsive to sActRIIB-mFc treatment. In addition, older oim/oim mice may have undergone fractures (possibly an accumulation of fractures) compared with younger oim/oim mice, with these fractures potentially decreasing mobility and impacting muscle mass and function.
Increased muscle mass with sActRIIB-mFc treatment was also concomitant with increased myofiber CSA, with sActRIIB-mFc-treated mice exhibiting increased Sol, Gast, and TA myofiber CSA compared with vehicle-treated mice, regardless of sex and genotype, although oim/oim mice did not reach significance (Fig. 4) . Previous studies in dystrophic muscle mouse models have also reported increases in muscle mass and myofiber CSA. [23] [24] [25] [26] 28 Interestingly, MacDonald et al. reported that muscle atrophy in mice due to surgical denervation was not protected by soluble ActRIIB treatment, suggesting increased muscle mass and force via myostatin inhibition may not be effective when there is deterioration of the neuromuscular junction. 42 Muscle atrophy and/or weakness in OI has generally been FIGURE 5. The oim/oim mice had reduced absolute and relative peak tetanic force (P o ) compared with WT and 1/G610C counterparts (A-F). sActRIIB-mFc-treated oim/oim mice exhibited increased peak P o compared with vehicle-treated counterparts (A, C, E). sActRIIB-mFc-treated WT and 1/G610C mice exhibited reduced relative peak tetanic force compared with vehicle-treated counterparts (B, D, F). (A) Sol peak tetanic force (P o ), (B) Sol relative P o , (C) Gast peak P o , (D) Gast relative P o , (E) TA peak P o , and (F) TA relative P o of 4-month-old WT, 1/G610C, and oim/oim vehicle-treated (solid bars: control) and sActRIIB-mFc-treated (open bars) mice (n 5 10-30 per group; TA peak P o : n 5 6-16 per group). The genotype main effect was evaluated. Gast and Sol values are presented as least-squares mean 6 standard error of the combined genotype values, regardless of sex, and the TA exhibited a genotype 3 sex interaction, with values (least-squares mean 6 standard error) separated by sex and genotype. *P < 0.05 and † P < 0.05 vs. WT 1 vehicle-treated mice.
attributed to immobilization, secondary impacts of neurological impairment or orthopedic casting, and prolonged bed rest due to fractures. 43 To determine whether the increase in muscle mass and myofiber CSA were associated with improved muscle function, we evaluated the contractile generating force of the Sol, Gast, and TA muscles. Surprisingly, sActRIIB-mFc-treated oim/oim mice exhibited increased absolute whole muscle contractile force in Sol, Gast, and TA muscles compared with vehicle-treated counterparts, whereas WT and 1/G610C mice showed only increasing trends (Fig. 5) . Although other studies of mouse models with muscle atrophy showed that soluble ActRIIB treatment increased absolute muscle FIGURE 6 . sActRIIB-mFc-treated 1/G610C mice Gast muscle had reduced specific tetanic force [specific P o (peak P o / muscle myofiber CSA)] compared with vehicle-treated counterparts (B). sActRIIB-mFc-treated male WT and 1/G610C mice TA muscle had reduced specific P o compared with vehicle-treated counterparts (C). (A) Sol specific P o , (B) Gast specific P o , and (C) TA specific P o of 4-month-old WT, 1/G610C, and oim/oim vehicle-treated (solid bars: control) and sActRIIB-mFc-treated (open bars) mice (n 5 9-12 per group; TA muscle groups: n 5 4-7). The genotype main effect was evaluated. Gast and Sol values are presented as least-squares mean 6 standard error of the combined genotype values, regardless of sex, and the TA exhibited a genotype 3 sex interaction, with values (least-squares mean 6 standard error) separated by sex and genotype. *P < 0.05; † P < 0.05 vs. WT 1 vehicle-treated mice. contractile function of compromised muscle, 23, 24, 28, 44 there were also reports of earlier muscle fatigability, 26, 45 decreased gene expression of components involved in mitochondrial function and oxidative phosphorylation, 46, 47 and reduced myofiberspecific function in mdx mice (mouse model of Duchenne muscular dystrophy) with treatment of higher concentrations of soluble ActRIIB. 25 Consistent with these studies, myostatin knockout (MSTN 2/2 ) mice exhibited centralized nuclei, a sign of muscle degeneration, and reduced relative muscle contractile function compared with WT and heterozygous myostatin-deficient (MSTN 1/2 ) littermates, 48 suggesting that a complete absence of myostatin is detrimental to muscle myofiber function.
Our results demonstrate sActRIIB-mFc-treated oim/oim mice were able to produce higher or equivalent levels of relative and specific muscle contractile forces compared with vehicle-treated counterparts, whereas WT and 1/G610C mice exhibited decreases in relative and specific muscle contractile forces in their Gast and TA muscles. The percent decrease in relative contractile force of sActRIIB-mFc-treated WT and 1/G610C Gast and TA muscles [male WT: 223% (Gast) and 230% (TA); male 1/G610C: 236% (Gast) and 243% (TA); see Table S3 online] were greater relative to age-matched 4-month-old heterozygous MSTN 1/2 mice [male: 218% (Gast) and 230% (TA)], 48 but not as robust as myostatin knockout (MSTN 2/2 ) mice [male: 239% (Gast) and 239% (TA)]. 48 These data suggest that sActRIIB-mFc treatment (biweekly, 10 mg/kg) may reduce available myostatin levels to below that present in MSTN 1/2 mice. Unlike MSTN 2/2 mice, heterozygous MSTN 1/2 had increased muscle mass with mild lesions without exhibiting a dramatic decrease in relative contractile function. 48 Consistent with the reported MSTN 1/2 findings, whippet dogs heterozygous for a myostatin mutation exhibited better racing performance than normal Whippet dogs or Whippets homozygous for the MSTN defect. 49 These data suggest that the magnitude of myostatin inhibition is critical to muscle function and exercise performance.
The observed improvement of oim/oim muscle contractile function with ActRIIB-mFc treatment, not seen in WT or 1/G610C muscle, may be due to inherent differences in the basal levels of muscle function. Children with OI can experience multiple fractures that can hamper their daily activity leading to hypoactivity and muscle atrophy. van Brussel et al. reported greater degrees of improvement in muscle force and aerobic capacity in OI type I and IV children with well-tailored physical training compared with healthy individuals. 40 Analogous to human OI individuals, hypoactivity in oim/oim mice can contribute to muscle weakness. The lower basal level muscle strength of oim/oim mice may have greater capacity to respond to myostatin inhibition as reflected by the increase in muscle contractile function with ActRIIB-mFc treatment relative to WT and 1/G610C mice.
Physical exercise contributes to bone health either directly or indirectly via muscle loads during prepubertal/pubertal growth in healthy children; a 6-year exercise program in healthy children demonstrated improved bone geometry with increased bone mass. 50 However, OI children often have reduced physical activity levels and exhibit decreased exercise tolerance compared with healthy, agematched individuals. 15, 51 This has been postulated to be associated with pain and/or behavioral choices due to concerns of fracture. 40, 52 Similarly, oim/oim mice exhibit reduced activity levels, which, in addition to muscle weakness, may reflect complications due to skeletal deformity or activity-associated pain. Although we have not addressed the impact of pain in oim/oim mice, in another OI mouse model, Col1a1
Jrt/1
, there was hypersensitivity to mechanical, heat, and cold stimuli; reduced locomotor activity; and increased limping. 53 Treatment with sActRIIB-mFc resulting in improved muscle function may also facilitate motor function of oim/oim mice, which may then allow development of tailored exercise regimens to further improve both the muscle and bone. The mdx mouse is characterized by reduced aerobic metabolism and muscle wasting. The combination of exercise and administration of sActRIIB-mFc in the mdx mouse was more effective in reconditioning the skeletal muscle gene expression profile to reflect healthy WT mouse muscle than either exercise or sActRIIB-mFc treatment alone. 54 In addition, further improvement in muscle and bone properties has been shown with a combination of myostatin deficiency and exercise in MSTN 2/2 mice. 55 In a separate study, neutralizing myostatin antibodytreated 24-month-old mice undergoing treadmill exercise demonstrated improved exercise performance with increased habitual ambulatory activity relative to either antibody treatment or treadmill exercise alone. 56 Several studies have raised concerns about impairment of mitochondrial function with myostatin inhibition. A limited group of studies in MSTN 2/2 mice demonstrated increased force production that was not proportional to their muscle hypertrophy, which may have reflected decreased mitochondrial function, [45] [46] [47] 57 muscle fiber type switching, 57, 58 deficits in oxidative metabolism that can lead to decreased endurance capacity, [57] [58] [59] [60] and/or decreased capillary density in muscle that alters the aerobic metabolism. 58 Unlike MSTN 2/2 mice, Bechir and colleagues found that energy status and function of glycolytic muscles were not disturbed during 6-minute fatigue exercise with ActRIIB blockade in both WT and mdx mice. 44 We examined citrate synthase activity, a measure of mitochondrial content and function, in the mixed Gast muscle and found that it was not altered by sActRIIBmFc treatment for any genotype studied. This suggests blockade of myostatin via sActRIIB-mFc does not alter this marker of mitochondrial function in Gast muscles. Interestingly, oim/oim Gast muscle showed greater citrate synthase activity than WT or 1/G610C Gast muscle (116%), which may reflect compensatory upregulation of oim/oim mitochondrial function to offset its compromised muscle function.
In conclusion, muscle weakness is often observed in individuals with OI, and clinicians encourage physical exercise to strengthen both the muscle and bone properties. Depending on clinical severity, individuals with OI may be limited in their options for exercise. Our study has demonstrated that sActRIIB-mFc-treated oim/oim mice, which model the moderately severe type III OI in humans, exhibited increases in muscle mass with improved contractile function without any apparent adverse effects, whereas the WT and 1/G610C mice treated with sActRIIB-mFc exhibited compromised muscle function. Further study is required on the underlying mechanisms responsible for the improved muscle function in oim/oim mice undergoing sActRIIBmFc treatment and the differential response of WT and 1/G610C mice. This investigation has provided new insight and potential clues to the design of new approaches for improving muscle and/or bone properties in OI.
